Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience.
Open Access
- 14 March 2022
- journal article
- research article
- Vol. 93 (1) , e2022158
Abstract
Glucose dysregulation (GD) in patients with β-thalassemia major (β-TM) usually develops gradually. Prediabetes consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), the latter detected by a standardized oral glucose tolerance test (OGTT). Diagnosis of prediabetes is essential for an early identification of high-risk individuals who will benefit from intensive iron chelation therapy and lifestyle modification. Therefore, patients with β-TM should undergo annual screening for glucose abnormalities, according to international recommendations, starting from the age of 10 years. OGTT remains the preferred screening method as it is more sensitive for GD than fasting plasma glucose (FPG), although it is poorly reproducible. The use of HbA1c measurement has limited use as it is generally considered unreliable in patients with thalassemia. Continuous glucose monitoring system (CGMS) is an accurate method to detect the variability of glucose fluctuations and offers the opportunity for better assessment of glucose homeostasis in a selected group of β-TM patients. Pancreatic Magnetic Resonance Imaging (MRI) associated with insulin secretion-sensitivity index-2 (ISSI-2) could be a complementary test, minimizing the necessity for OGTT and identifying high-risk patients before irreversible pancreatic damage occurs. The aims of this short report are to give practical guidance for an early identification of GD in β-TM patients, to summarise our experience, and to offer an impetus for further research in the field.Keywords
This publication has 39 references indexed in Scilit:
- Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young ageAmerican Journal of Hematology, 2013
- The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazoleAmerican Journal of Hematology, 2013
- Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidanceBMJ, 2012
- Regulation of Hepatic Glucose Uptake and Storage In VivoAdvances in Nutrition, 2012
- Pancreatic iron and glucose dysregulation in thalassemia majorAmerican Journal of Hematology, 2011
- Management of transfusional iron overload – differential properties and efficacy of iron chelating agentsJournal of Blood Medicine, 2011
- Hormonal Regulation of Hepatic Glucose Production in Health and DiseaseCell Metabolism, 2011
- Distribution of fasting plasma glucose and prevalence of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes in the Mexican paediatric populationPaediatric and Perinatal Epidemiology, 2009
- Effect of enhanced iron chelation therapy on glucose metabolism in patients with β‐thalassaemia majorBritish Journal of Haematology, 2006
- Diabetic Nephropathy in Hypertransfused Patients With β-Thalassemia: The role of oxidative stressDiabetes Care, 1998